Results 201 to 210 of about 1,271,973 (317)

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

open access: yesMolecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller   +10 more
wiley   +1 more source

Predictive value of ALBI score in assessing prognosis of NSTEMI: a retrospective cohort study. [PDF]

open access: yesFront Cardiovasc Med
Chen X   +7 more
europepmc   +1 more source

The Predictive Value of Monocarboxylate Transporter 4 (MCT4) on Lung Adenocarcinoma Patients Treated with PD-1 Inhibitors

open access: yes
Qinghua Zhang,1,* Guizhen Pan,2,* Lu Zhang,1 Yidan Xu,1 Jiqing Hao1 1Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, People’s Republic of China; 2Department of Radiation Oncology, The ...
Pan G, Hao J, Zhang L, Zhang Q, Xu Y
core  

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

open access: yesMolecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi   +11 more
wiley   +1 more source

Predictive Value of Semi-Quantitative GeneXpert Categories for Microbiological Outcomes in Pulmonary Tuberculosis. [PDF]

open access: yesBiomedicines
Cojocaru E   +5 more
europepmc   +1 more source

Predictive Value of Plasma D-Dimer for Cerebral Herniation Post-Thrombectomy in Acute Ischemic Stroke Patients

open access: yes
Wensheng Zhang,1,2,* Weifang Xing,1,* Jiyun Feng,3,* Yangchun Wen,1 Xiaojing Zhong,1 Li Ling,2,4 Jinzhao He1,5 1Department of Neurology, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, People’s ...
Zhang W   +6 more
core  

Home - About - Disclaimer - Privacy